Vietnam’s pharmaceutical industry has entered a decisive new phase of global relevance. Once largely focused on meeting domestic healthcare needs, the country has steadily expanded its manufacturing capacity, regulatory sophistication, and export reach. Today, Vietnam is no longer viewed merely as a low-cost producer but as a credible regional supplier of pharmaceutical products across Asia, Africa, and emerging global markets.
According to Vietnam pharmaceutical export data, the country’s pharmaceutical exports reached USD 312 million in 2025, reflecting an 11% year-on-year increase from 2024. This growth builds on a solid upward trend, as exports totaled USD 279.20 million in 2024, marking an 8% increase from the previous year. These figures underscore growing international confidence in Vietnamese drug manufacturing, quality compliance, and cost competitiveness.
This article presents a comprehensive, data-driven analysis of Vietnam’s pharmaceutical export performance in 2025, examining export trends, destination markets, product segmentation, regulatory developments, key challenges, and future opportunities.
Overview of Vietnam’s Pharmaceutical Export Performance (2020–2025)
Over the past five years, Vietnam’s pharmaceutical exports have demonstrated consistent growth despite global disruptions, supply-chain volatility, and regulatory challenges. Based on Vietnam pharmaceutical export data, export values evolved as follows:
- 2020: USD 206 million
- 2021: USD 174 million
- 2022: USD 261 million
- 2023: USD 258 million
- 2024: USD 279 million
- 2025: USD 312 million
This trajectory represents a compound annual growth rate (CAGR) of approximately 7–8%, outperforming several other manufacturing segments in Vietnam. The rebound after 2021 reflects stronger regional demand, improved compliance with international quality standards, and increased capacity utilization at GMP-certified facilities.
Key growth drivers include rising demand for affordable generics, ASEAN trade integration, improved quality control systems, and expanding exports to Asia, Africa, and the Middle East.
Vietnam Pharmaceutical Export Performance & Industry Landscape in 2025
In 2025, Vietnam Pharmaceutical Export value reached USD 312 million, positioning Vietnam as the 4th largest pharmaceutical exporter in Southeast Asia. This ranking highlights Vietnam’s steady progress in a region dominated by established exporters such as Singapore and Thailand.
Vietnam’s domestic pharmaceutical market is expanding at 6–8% annually, with total market size expected to reach USD 8 billion by 2026, up from USD 2.7 billion in 2015. This strong domestic base supports export growth by encouraging scale, quality upgrades, and product diversification.
Exporting Companies and Ownership Structure
There are 67 companies actively engaged in pharmaceutical and drug-ingredient exports. Foreign-invested enterprises contribute approximately 75% of total export value, while domestic firms account for the remaining share. This hybrid structure has helped transfer technology, improve compliance, and integrate Vietnam into global pharmaceutical supply chains.
Manufacturing Capacity and Quality Standards
Vietnam’s pharmaceutical manufacturing ecosystem has undergone significant transformation. As of 2025:
- 243 manufacturing plants comply with WHO-GMP standards
- 29 plants meet higher international standards such as EU-GMP or PIC/S-GMP
- Domestic production supplies 60% of local demand by volume and 46% by value
Vietnam is capable of producing all 13 essential drug groups defined by the World Health Organization and manufactures 11 of the 12 vaccines in the national Expanded Immunization Program.
These improvements, reflected in Vietnam pharma export statistics, are central to Vietnam’s growing acceptance in regional and emerging markets.
Vietnam Pharmaceutical Exports by Country: Key Destination Markets
An analysis of Vietnam pharmaceutical export data by country shows that exports are regionally diversified, with Asia accounting for the largest share.
Top Export Destinations (2024–25)
- Japan – USD 60.74 million (21.8%)
- South Korea – USD 27.61 million (9.9%)
- Cyprus – USD 26.69 million (9.6%)
- Cambodia – USD 23.45 million (8.4%)
- Philippines – USD 20.63 million (7.4%)
- Germany – USD 10.05 million (3.6%)
- Saudi Arabia – USD 9.32 million (3.3%)
- China – USD 7.99 million (2.9%)
- Hong Kong – USD 7.81 million (2.8%)
- Malaysia – USD 7.72 million (2.8%)
Japan and South Korea stand out for their stringent quality requirements, indicating rising trust in Vietnamese pharmaceutical standards. ASEAN neighbors such as Cambodia and the Philippines remain vital markets due to geographic proximity and regulatory alignment.
Product Breakdown of Vietnam’s Pharmaceutical Exports
Generic Finished Formulations (55–60%)
Generic medicines form the backbone of Vietnam pharmaceutical exports, including tablets, capsules, antibiotics, cardiovascular drugs, and diabetes treatments. Competitive pricing and WHO-GMP compliance make these products attractive in price-sensitive markets.
Traditional and Herbal Medicines (15–18%)
Vietnam is a leading exporter of herbal medicines in Southeast Asia. Products such as plant-based supplements and traditional formulations benefit from Vietnam’s biodiversity and strong traditional medicine heritage.
Vaccines and Biological Products (10–12%)
While limited in scale, vaccine exports play a strategic role in regional public health programs. State-linked manufacturers dominate this segment.
APIs and Intermediates (8–10%)
Vietnam remains partially dependent on imported APIs, particularly from China and India, as shown by vietnam import customs data. However, local production of basic APIs is gradually increasing.
Leading Pharmaceutical Exporters in Vietnam
Key pharmaceutical exporters in Vietnam include:
- DHG Pharma: Strong in generics and herbal products
- Traphaco: Specializes in traditional medicines
- Pymepharco: Focused on antibiotics and injectables
- Imexpharm: EU-GMP compliant, export-oriented generics
- VABIOTECH: Vaccines and biological products
These firms play a critical role in shaping Vietnam’s export reputation.
Regulatory Reforms and Digital Transformation
Vietnam’s export readiness is strongly supported by regulatory modernization. Administrative procedures were reduced by nearly 40%, and over 47 pharmaceutical public services are now available online. In 2025 alone, more than 40,000 applications were processed for drug registration and export approvals, with 94% completed on time.
Alignment with ASEAN Common Technical Dossier standards and strengthened pharmacovigilance systems have further boosted buyer confidence.
Challenges Facing Vietnam’s Pharmaceutical Exports
Despite progress, challenges remain. API dependence exposes exporters to supply risks, while limited presence in highly regulated markets like the US and EU restricts growth. Brand recognition is still developing, and R&D investment lags behind global leaders.
Export Outlook: 2026–2030
Looking ahead, Vietnam Pharmaceutical Export value is projected to exceed USD 400 million by 2030 under favorable conditions. Growth will be driven by deeper penetration into Africa and ASEAN, expansion of EU-GMP capacity, and gradual entry into regulated markets with select products.
Conclusion
In conclusion, Vietnam pharmaceutical export data for 2025 confirms that Vietnam has firmly established itself as a reliable regional exporter of affordable, quality medicines. While it is not yet a global pharmaceutical powerhouse, the momentum is undeniable. With continued regulatory reform, manufacturing upgrades, and strategic market expansion, Vietnam’s pharmaceutical export story is no longer emerging—it is actively unfolding across global trade networks and vietnam exports more broadly.
